Malaria
Conditions
Brief summary
This study is a phase 2b, placebo controlled, randomized, blinded study of the efficacy of WR 238605, a new primaquine analog, compared to placebo as chemosuppression of P. falciparum malaria in Nyanza Province, western Kenya.
Interventions
DRUGTafenoquine
Tafenoquine 200mg and 400 mg
OTHERPlacebo
Placebo
Sponsors
SmithKline Beecham
U.S. Army Medical Research and Development Command
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Healthy subjects (male or female) 2. Age of 18-55 years 3. Residing in one of the study villages of the Nyanza Province for the entire study
Exclusion criteria
1. Any cardiovascular, liver, neurologic, or renal functional abnormality which in the opinion of the clinical investigators would place the subject at increased risk of an adverse event or confuse the result. 2. Female subjects who were pregnant (Positive serum / plasma -HCG as tested within 48 hours of first drug administration). 3. Use of antimalarial drugs not prescribed by study physicians within 2 weeks of study drug initiation. 4. Clinically significant abnormalities (including but not limited to abnormal hepatic or renal function) as determined by history, physical and routine blood chemistries and complete blood count. 5. Known hypersensitivity to any study drug. 6. Unwilling to remain in area and report for drug administration and blood drawing during the duration of the study. 7. Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prophylactic outcome. | 13 Weeks | Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells. A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prophylactic outcome after 7 weeks | 7 Weeks | Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells. A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites. |
| Prophylactic outcome after 10 weeks | 10 Weeks | Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells. A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites. |
Outcome results
None listed